参考文献 References
[1] 国家药品监督管理局.2023年度药品审评报告. https://www.nmpa.gov.cn/so/s?tab=all&qt=2023%E8%8D%AF%E5%93%81%E5%AE%A1%E8%AF%84%E6%8A%A5%E5%91%8A.
[2] 国家药品监督管理局药品审评中心.药物临床试验的一般考虑指导原则.(2017-01-18).
[3] FDA. Adaptive designs for clinical trials of drugs and biologics [EB/OL]. (2019-11-29) [2021-11- 25]. https: // www. fda. gov /regulatory-information/search-fda-guidance -documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance industry.
[4] 李若冰.抗肿瘤药物早期临床研究的新颖试验设计方法.中国新药杂志,2021,30(24).
[5] RUPPERT AS,SHOBEN AB. Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs[J]. Contemp Clin Trials Commun,2018,12: 40-50.
[6] 赵耐青 主编. 卫生统计学.高等教育出版社,2013-2
[7] 陈峰, 夏结来, 主编. 临床试验统计学. 北京: 人民卫生出版社, 2018: 202-210.
[8] 郑晓娜. 多组独立资料方差分析的方法和注意事项. 中国医药指南, 2019, 17(27): 122-123.
[9] 史天宇, 王艳, 杨琳. 多组独立资料方差分析方法及其应用. 中国卫生统计, 2018, 35(1): 46-49.
[10] ICH. E9: statistical principles for clinical trials. Available at: https://wenku.baidu.com/view/9785232a647d27284b 735117.html.
[11] FDA. Adjusting for covariates in randomized clinical trials for drugs and biologics with continuous outcomes. Washington DC: FDA, 2019.
[12] Altman DG, Doré CJ. Randomisation and baseline comparisons in clinical trials. Lancet, 1990, 335(8682): 149-153.
[13] Begg CB. Significance tests of covariate imbalance in clinical trials. Control Clin Trials, 1990, 11(4): 223-225.
[14] 国家药品监督管理局药品审评中心. 抗肿瘤药物临床试验终点技术指导原则(2012-05-15).
[15] 郭浩然, 胡孟璇. 肿瘤治疗效果及预后因素的评价方法——小样本Kaplan-meier生存率估计及Log-Rank检验. 数理医药学杂志,1992,5(1):62-66.
[16] 余红梅,罗艳虹,张岩波,陈芊. 生存分析log-rank检验样本含量估计影响因素. 中国卫生统计,2012,29(2): 161-163.
[17] 朱玉芳, 李晶, 吴晓. 生存分析方法在临床试验中的应用. 中国药物经济学, 2019, 14(4): 26-29.
[18] 李悦, 汪芳. 生存分析中的统计方法与应用. 中国卫生统计, 2018, 35(4): 563-565.
[19] 陈文静. 生存分析方法的理论及应用. 中国医药指南, 2019, 17(31): 140-141.
[20] Liu JP, Chow SC. Sample size calculation for clinical trials: theory and practice. Springer Science & Business Media, 2017.
[21] Wang Y, Bakhai A. Sample size calculation for clinical trials: the importance of rigorous study design. Contemporary Clinical Trials Communications, 2018, 11: 81-87.
[22] Li G, Taljaard M, Van den Heuvel ER, Levine MA. Calculating sample size using the difference in two means: considerations and methods. BMC Medical Research Methodology, 2014, 14(1): 41.
[23] Pocock SJ. Clinical Trials: A Practical Approach. John Wiley & Sons, 2013.
[24] Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Springer Science & Business Media, 2010.
[25] Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Springer Science & Business Media, 2010.
[26] Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. International Journal of Epidemiology, 2006, 35(5): 1292-1300.
[27] Campbell MK, Fayers PM, Grimshaw JM. Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research. Clinical Trials, 2005, 2(2): 99-107.
[28] Parker RA, Eaton CA. Control of center effects in multicenter trials. Academic Radiology, 2002, 9(5): 517-521.
[29] Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 2007, 357(21): 2189-2194.